紫杉醇和顺铂腹腔热灌注化疗对晚期卵巢癌满意细胞减灭术后的疗效观察

The Clinical Observation of Paclitaxel and Cisplatin Combined with Intraperitoneal Perfusion Chemotherapy in the Treatment of Advanced Ovarian Cancer

目的探讨比较紫杉醇和顺铂腹腔热灌注化疗在晚期卵巢癌满意细胞减灭术后的疗效。方法选取2013年7月~2015年7月收治的40例晚期卵巢癌患者为研究对象,行满意卵巢癌细胞减灭术后,依据随机数字法分为试验组和对照组。试验组给予紫杉醇+顺铂腹腔热灌注化疗联合静脉化疗,对照组给予紫杉醇+顺铂方案静脉化疗。观察两组患者的临床疗效和不良反应。结果两组术后的CA125水平比较,差异无统计学意义(P>0.05)。热灌注后试验组平均CA125值降至21.6U·mL^(-1),对照组平均CA125值降至95.5 U·mL^(-1),差异有统计学意义(P<0.05)。试验组化疗不良反应的发生率与对照组比较,差异无统计学意义(均P>0.05)。试验组CD3+、CD4+和CD4+/CD8+值均较治疗前明显增高(P<0.05),免疫状态明显改善,对照组变化不明显。结论紫杉醇和顺铂腹腔热灌注化疗方案治疗晚期卵巢癌,可提高临床疗效,未见明显不良反应。

OBJECTIVE To investigate the clinical efficacy of Paclitaxel and Cisplatin combined with intraperitoneal hyperthermic perfusion chemotherapy on advanced ovarian cancer patients. METHODS Forty cases with advanced ovarian cancer treated in our hospital from July 2013 to May 2015 were divided into observation group and control group by random numbers after satisfied cytoreductive surgery. The observation group were treated with Paclitaxel and Cisplatin combined with intraperitoneal hypothermic perfusion chemotherapy, and the control group were treated with Paclitaxel and Cisplatin combined with intravenous chemotherapy. The clinical efficacy and toxicity of two group were observed. RESULTS There was no significant differences in CA125 level in the two groups after surgery （P〉0.05）. The mean level of CA125 in the treatment group fall to 21.6 U.mL-1after aperitoneal hyperthermic chemotherapy, while in the contrast group,it was 95.5 U .mL-1（P〈0.05）. Compared with the control group, there was no significant difference in the incidence of adverse reactions in the experimental group （P〉 0.05）. CD3 ＋, CD4＋ and CD4＋/CD8＋of experimental group were significantly higher than before treatment （P〈 0.05 ）, and immune status improved significantly, while the control group did not change significantly. CONCLUSION The clinical application of Paclitaxel and Cisplatin combined with intraperitoneal hypothermic perfusion chemotherapy can improve the clinical efficacy, reduce the adverse reaction rate and be of safty. thus, it is worthy of clinical application.